Literature DB >> 20580868

HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis.

J C Morales1, M J Ruiz-Magaña, D Carranza, G Ortiz-Ferrón, C Ruiz-Ruiz.   

Abstract

Epigenetic modifications commonly associated with tumor development, such as histone deacetylation, may influence the resistance of some tumor cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) by regulating gene transcription of components of the TRAIL signalling pathway. In the present study we have analyzed the effect of six different histone deacetylase inhibitors (HDACi), belonging to the four classic structural families, on TRAIL-induced apoptosis in leukemic T cell lines. Non-toxic and functional doses of all HDACi but apicidin, similarly sensitized different leukemic T cell lines to TRAIL-induced apoptosis, while they showed no effect on the resistance of normal T lymphocytes. Sensitizing doses of vorinostat, valproic acid, sodium butyrate and MS-275 regulated the expression of TRAIL-R2, c-FLIP and Apaf-1 in leukemic cells while TSA modulated only the expression of Apaf-1. The synergistic effect of all HDACi and TRAIL was inhibited in Bcl-2-overexpressing leukemic T cells. Thus, different HDACi may affect the expression of different TRAIL-related genes, but regulation of the mitochondrial pathway seems to be essential for the TRAIL sensitizing effect of HDACi in leukemic T cells. Overall, HDACi represent a promising and safe strategy in combination with TRAIL for treatment of T-cell leukaemia. 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20580868     DOI: 10.1016/j.canlet.2010.04.029

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

1.  Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme.

Authors:  Filiz Senbabaoglu; Ahmet Cingoz; Ezgi Kaya; Selena Kazancioglu; Nathan A Lack; Ceyda Acilan; Tugba Bagci-Onder
Journal:  Cancer Biol Ther       Date:  2016-03-30       Impact factor: 4.742

2.  Trichostatin A potentiates TRAIL-induced antitumor effects via inhibition of ERK/FOXM1 pathway in gastric cancer.

Authors:  Lin Li; Biao Fan; Lian-Hai Zhang; Xiao-Fang Xing; Xiao-Jing Cheng; Xiao-Hong Wang; Ting Guo; Hong Du; Xian-Zi Wen; Jia-Fu Ji
Journal:  Tumour Biol       Date:  2016-02-01

Review 3.  Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.

Authors:  Michael Dickinson; Ricky W Johnstone; H Miles Prince
Journal:  Invest New Drugs       Date:  2010-12-14       Impact factor: 3.850

4.  The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.

Authors:  Ryan C Thompson; Iosif Vardinogiannis; Thomas D Gilmore
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

5.  The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer.

Authors:  Fabien J Cousin; Sandrine Jouan-Lanhouet; Nathalie Théret; Catherine Brenner; Elodie Jouan; Gwénaëlle Le Moigne-Muller; Marie-Thérèse Dimanche-Boitrel; Gwénaël Jan
Journal:  Oncotarget       Date:  2016-02-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.